Exposure–response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study

Rong Deng,Leonid Gibiansky,Tong Lu,Xiaobin Li,Dan Lu,Chunze Li,Sandhya Girish,Jue Wang,Michelle Boyer,Noopur Shankar,Kathryn Humphrey,Kevin J. Freise,Ahmed Salem,John F. Seymour,Arnon P. Kater,Dale Miles

Exposure–response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study

2019

Rong Deng
Leonid Gibiansky
Tong Lu
Xiaobin Li
Dan Lu
Chunze Li
Sandhya Girish
Jue Wang
Michelle Boyer
Noopur Shankar
Kathryn Humphrey
Kevin J. Freise
Ahmed Salem
John F. Seymour
Arnon P. Kater
Dale Miles

AbstractExposure–response relationships from a phase 1b (M13-365) and phase 3 (MURANO) study were investigated to assess benefit/risk of venetoclax 400 mg daily plus rituximab in relapsed/refractor...

Keywords:

Diabetes mellitus
Chronic lymphocytic leukemia
Oncology
Rituximab
Immunology
Medicine
Refractory Chronic Lymphocytic Leukemia
Internal medicine
Venetoclax
in patient
exposure response

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations